Software facilitates screen-to-lead research data analysis.October 9, 2007 -
Combining screening data with chemical, pharmacological, and in vivo data, Screener® v5.0 generates information scientists need to prioritize compounds and identify quality lead structures. Enterprise solution integrates enterprise assay data management with processing workflows and analysis tools while providing access to range of information from other research and drug discovery systems as well. Data handling is independent of instrumentation, technology, volume, and location.
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Original Press release
Genedata AG
Maulbeerstrasse 46
Basel, , CH-4016
Switzerland
New Data Analysis and Management Solution Genedata Screener 5.0 Increases Productivity from Screen to Leads
Basel, September 26, 2007 -- Genedata, a leading provider of drug discovery informatics, today announced the release of Genedata Screener® Version 5.0, an enterprise solution for screen-to-lead research data analysis and management.
Screener 5.0 combines enterprise assay data management with high-performance processing workflows and flexible analysis tools. In addition, it provides access to a wide range of information from other reseach and drug discovery systems. From low to ultra-high throughput screens, from single-point assays to complex high content screens - Screener rapidly analyzes, integrates, and manages all assay data, independent of instrumentation, technology, volume or location. Screening data is combined with chemical, pharmacological and in vivo data to generate exactly the information scientists need to prioritize compounds and identify quality lead structures with the highest confidence. Screener`s open and scalable architecture integrates with the existing corporate infrastructure as well as third party solutions and provides access to information from other corporate sources. Screener can be tailored to specific discovery processes, making it an integral as well as flexible element maximizing it`s value.
"Drug discovery processes are increasingly owned by interdisciplinary project teams. Compound screening using a portfolio of new technologies has become a strong support function for these teams, and screening data is regarded as an asset to be reused across the organization, for multiple projects. This demands comprehensive data management, stringent quality control, and the integration of information," explains Dr. Stephan Heyse, Business Head of Genedata Screener. "Screener 5.0 enables drug researchers to focus on their primary objectives: to quickly evaluate entire campaigns, to compile and share relevant information for their specific projects, and to confidently identify high quality lead structures. No other solution on the market provides such comprehensive data analysis and management features at such a high level of performance."
Contact Genedata
Christiane Becker
Public Relations
Phone +41 61 697 7378
Fax +41 61 697 7244
christiane.becker@genedata.com
www.genedata.com
About Genedata Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data; Genedata Screener® for screening analysis; and Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin-off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Tokyo (Japan), Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Taiwan and Singapore. For more information about Genedata, please visit: www.genedata.com.
|
|
|
|
|
|
|
|
